Product Description
Dacarbazine is used to treat melanoma (a type of skin cancer) that has spread to other parts of your body. Dacarbazine is also used in combination with other medications to treat Hodgkin's lymphoma (Hodgkin's disease; a type of cancer that begins in a type of white blood cells that normally fights infection). Dacarbazine is in a class of medications known as purine analogs. It works by slowing or stopping the growth of cancer cells in your body. (Sourced from: https://medlineplus.gov/druginfo/meds/a682750.html)
Mechanisms of Action: DNA Mtase Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Lebanon | Lithuania | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Kingdom | United States | Uruguay | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Belgium, Brazil, Czech Republic, Denmark, France, Germany, Hungary, Ireland, Israel, Italy, Japan, Netherlands, New Zealand, Norway, Poland, Slovakia, Spain, Sweden, Switzerland, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 14
Highest Development Phases
Phase 3: Hodgkin Lymphoma|Leiomyosarcoma|Liposarcoma|Melanoma|Neuroblastoma
Phase 1: Ischemic Stroke
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| HR-NBL2 | P3 |
Active, not recruiting |
Neuroblastoma |
2031-09-24 |
|
| STRASS 2 | P3 |
Unknown status |
Leiomyosarcoma|Liposarcoma |
2027-12-16 |
|
| cHL 001 | P2 |
Recruiting |
Hodgkin Lymphoma |
2027-10-03 |
|
| NCT06377566 | P2 |
Recruiting |
Hodgkin Lymphoma |
2027-04-01 |